bioskin® Presents 5th Dermatological Product Development Workshop June 13 - 14, 2013 in Munich, Germany

NAPA, Calif., May 13, 2013 /PRNewswire/ -- bioskin® is an organizer and sponsor for the 5th Dermatological Product Development Workshop for the AGAH (Association of Applied Human Pharmacology), to be held June 13 – 14, 2013, in Munich, Germany.

Many of the key issues and challenges involved in the successful development of dermatological products will be addressed.

Practical and effective approaches to topical drug development will be covered including:

• Formulation, optimization and implementation of Quality by Design
• Role of in vitro testing in drug development and formulation optimization process 
• Innovative methodologies for analysis of drug delivery to the skin
• Proving the concept early on with skin biology models, biomarkers and exploratory clinical studies
• Optimizing preclinical development strategy
• Animal models in dermatology
• Getting regulatory filings right the first time
• Options for bioequivalence assessment of topical drugs
• Regulatory aspects of pediatric plans (PIPs)
• Role of global registration strategy in reducing development timelines

The workshop offers valuable information for all those interested in the development of dermatological products, whether these are NMEs, known drugs in novel formulations or generic drug products.

For more details and on-line registration visit http://www.bioskin.de/events.

About bioskin®:

bioskin® is a full-service CRO specialized in dermatology. We offer strategic planning and regulatory support for global dermatological product development as well as all core operational services for management of Phase I-IV clinical trials and medical device trials.

Contact Information:

Europe Office:                                                        
Betsy Hughes-Formella, PhD                                  
+49 40 60689713                                                     
Email 

US Office:
AJ Acker
1 (707) 260-9109
Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE bioskin